ADVA
11.3.2021 09:02:06 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5405-P substation grandmaster, an ultra-compact synchronization solution specifically designed for the digital transformation of power utility networks. The OSA 5405-P delivers the precise and reliable timing that utilities need to leverage new smart grid applications, including intelligent power generation, distribution and control systems. The solution protects mission-critical infrastructure from the risk of outages caused by loss of timing from satellite signals by combining GNSS receivers with accurate PTP grandmaster clocks and network-delivered timing. Available with rack, DIN rail and wall mounting options, the OSA 5405-P also reduces cost and complexity in synchronization networks. What’s more, by supporting both legacy and new timing technologies, the solution empowers utility networks to smoothly and cost-effectively transition to next-generation synchronization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005049/en/
“The utility network landscape is changing. With the move to distributed power generation and the digital transformation of substations, utilities face a new set of challenges and opportunities. To succeed, all processes must be tightly synchronized and a new level of accurate, robust timing is required. Our OSA 5405-P addresses these exact needs and offers power network operators a simple and affordable route from legacy synchronization to fully protected and assured PTP timing,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Now utility networks can leverage a solution tailored to their precise needs that’s easy to install anywhere. And with our sophisticated Ensemble Controller and Sync Director, synchronization is easy to manage and operate.”
The OSA 5405-P offers power network operators a risk-free way to migrate their existing timing infrastructure to the accurate and robust PTP timing needed for new automated technologies and smart grid applications. With network-based synchronization backing up timing from GNSS, the OSA 5405-P removes vulnerability to loss of satellite signals. It supports multiple PTP profiles, including the Power Profile, and features NTP as well as IRIG-B interfaces for precise time synchronization of all power system devices. Its Syncjack™ capabilities also deliver accurate, real-time monitoring of synchronization quality. The OSA 5405-P is the ultimate power utility synchronization solution where cost-efficiency and small footprint are key. With rack and DIN rail mounting options, it’s extremely versatile to deploy. Ideal for secondary substations, it can also complement the OSA 5422-IRIG solution in primary substations. The OSA 5405-P also utilizes in-service sync probing and assurance as well as innovative GNSS assurance capabilities.
“Smart grids need intelligent timing. That’s what our OSA 5405-P offers. It brings assured and protected synchronization to the edge of the power network in an extremely cost-efficient way. Now operators can rely on their infrastructure delivering the robust and accurate timing needed for new secondary substation and protection relay technologies,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “The compact and environmentally friendly design of our solution will be especially valuable as utility networks migrate to packet-based timing. The OSA 5405-P distributes accurate timing with the smallest size and power footprint on the market. That means major savings on rack space and a significant reduction in complexity.”
Further details on the OSA 5405-P are available in these slides: https://adva.li/osa-5405-p-slides .
A supporting solution brief can be downloaded here: https://adva.li/osa-5405-p-solution-brief .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005049/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
